Semaglutide Cost Without Insurance: The Routes, and What Sets the Number

You will not find a figure in this article, and the reason is not squeamishness. Cash pricing for semaglutide has been rewritten repeatedly over the past year, by the companies that make it and by the federal government, so a number typed into a sentence here is wrong by the time you read it. What holds still is the set of routes and what decides the arithmetic on each one. Read that here, then take the current figures from our live price tracker and the cheapest semaglutide board, where every one of them carries the date we captured it.

Four things set the number, and the seller is only one of them

Two people paying cash for “semaglutide” on the same day can pay very different amounts without either of them being cheated. Before you compare anything, work out which of these four you are looking at.

Route one — buy the approved drug from the company that makes it

Both manufacturers now run their own pharmacy channel, which did not exist when most of the advice on this subject was written. Novo Nordisk sells Wegovy and Ozempic through NovoCare Pharmacy, in pen and tablet form, and the page lets you pick a self-pay path or an insurance path before you see anything else.^[1] Lilly sells Zepbound to self-paying patients through LillyDirect under a program it calls the Zepbound Self Pay Journey Program.^[3] These are the same FDA-approved products a pharmacy would dispense, sold without a payer in the middle.

Two things about that channel are worth knowing before you use it, and neither is hidden — they are simply in the footnotes rather than the headline.

Paying cash can cost you twice

Novo's own explanation of its self-pay option is the clearest statement of the trade anyone has published, and it is quoted here in full because paraphrasing it would soften it.

If you don’t have insurance or elect not to use it, this is your cost. By opting to pay outside of your insurance, any money spent will not count toward your out-of-pocket limits or deductible.

— NovoCare Pharmacy, self-pay explanation, read 2026-08-15

If you genuinely have no drug coverage, that clause costs you nothing. If you have a plan with a deductible and you decide the cash route is simpler than fighting for coverage, it means a year of payments that leave your deductible exactly where it started.^[1] That is a genuine consideration, and by itself it settles nothing in either direction.

The opening figure and the standing figure are different objects

Novo's savings offer on this channel runs for a stated number of monthly fills, through a stated calendar date, after which a higher standing rate applies — and that standing rate is itself banded by strength.^[1] So a quote taken in your first month describes neither what you pay at month six nor what you pay when your dose moves up. Both companies also reserve the right to change or end these programs. Lilly's terms put it about as bluntly as terms are written: the offer may be terminated, rescinded, revoked, or amended at any time, with or without notice.^[3]

Route two — the federal price channel

There is now a government-run comparison site, trumprx.gov, whose own list carries Wegovy in both pill and pen form, Ozempic and Zepbound at what it labels most-favored-nation prices set against an original price.^[4] Medicare's consumer pages point people who fall outside its own GLP-1 program toward it.^[5] We are recording it here as a route that exists rather than as a recommendation: we could not retrieve that site's own frequently-asked-questions answers server-side, so this register makes no claim about how it handles insurance, pharmacies or refills. Check those against the seller you actually end up buying from, and against our tracker.

Route three — compounded, and what it is now

For three years the cheapest semaglutide in the country was compounded, and that was lawful mainly because the drug sat on FDA's shortage list. That condition is gone. The agency's enforcement discretion ran out on two separate dates — the twenty-second of April 2025 for state-licensed pharmacies working under section 503A, then a month later, on the twenty-second of May, for outsourcing facilities under 503B. At its update of April 1, 2026 the agency recorded that neither molecule now sits on the shortage list, nor on the bulks list that outsourcing facilities depend on.^[7] On April 30, 2026 it proposed striking semaglutide, tirzepatide and liraglutide from that bulks list altogether, on the ground that no clinical need exists for an outsourcing facility to build them from bulk substance.^[11]

Compounding a drug for one patient whose documented need an approved product cannot meet remains lawful and remains narrow. What ended was the version of it that funded a cheap national market. For the underlying rule, read which GLP-1s can be compounded; for what to do when your own program closes, read our guide to that situation. If a seller is still shipping compounded semaglutide at volume, the useful question is which basis it claims, and asking it before you enter a card costs nothing.

The part people skip: check whether you are actually uninsured for this

“Without insurance” is doing two different jobs in the search box. Sometimes it means no coverage at all. More often it means a plan that has already refused, and those are not the same position, because a refusal is usually specific to an indication rather than to a molecule.

The clearest evidence for that comes from Medicare's own consumer page. Its temporary GLP-1 program lists people with type 2 diabetes among those who are not eligible, and gives the reason in a parenthesis: their Part D plan might cover the drug already.^[5] The same logic runs through commercial plans. A plan that excludes weight management may still pay for the diabetes prescription, and the two are separate products carrying separate labels. Ozempic and Mounjaro are approved for blood-sugar control in type 2 diabetes; Wegovy and Zepbound are approved for weight reduction, and Zepbound additionally for moderate to severe obstructive sleep apnea.^{[8][9][10][12]} Which of those your prescriber writes is a clinical decision, not a billing tactic, and it is one to raise with them rather than to engineer.

Two further things are worth checking before you settle on cash.

• Medicare's GLP-1 Bridge, if you have Part D. CMS is running a short-term demonstration between July 1, 2026 and December 31, 2027, sitting outside the ordinary Part D machinery for coverage and payment, and covering Foundayo, Wegovy injection and tablets, and the KwikPen formulation of Zepbound only — the single-dose Zepbound vials and pens are excluded.^[6] Eligibility turns on age, BMI and a listed comorbidity, and a prescriber has to submit a prior authorization attesting to it.^[5][6] The list was last revised on April 6, 2026, so check it rather than trusting a summary, including this one.
• Savings cards, and the sentence that disqualifies most people. These are real and they are conditional. Novo's enrollment form asks up front whether you are enrolled in any government, state or federally funded medical or prescription benefit program, naming Medicare, Medigap, VA, DOD, TRICARE and Medicaid among the examples.^[2] Its self-pay footnotes say the same thing more briefly: government beneficiaries excluded.^[1] Lilly's savings-card terms run the other way for one product, requiring enrollment in a commercial drug insurance plan, and bar seeking reimbursement from any insurer, third party or health savings account.^[3] Read the eligibility text before you plan a budget around a card.

What to ask before you pay cash

1. Which brand am I being quoted, and at which strength? A figure without both is not a price.
2. What does this program define as one month? A box, a bottle, or a calendar month, and is there a refill window that ends my eligibility if I miss it?^[1][3]
3. Is this the introductory figure or the standing one? Ask for the date the introductory period ends and the figure that follows it, in writing.^[1]
4. What happens to this figure when my dose goes up? Get every rung, not the one you start on.^[1]
5. Does anything I pay here count toward my deductible? On a manufacturer self-pay path the answer is no, and the manufacturer says so itself.^[1]
6. Has anyone actually run a claim? If you have a plan, a denial for one indication is not a denial for the drug. Check what your plan and state do in our insurance register.
7. Is this the approved product or a compounded preparation? If compounded, on what basis, given that the shortage that supported it has ended?^[7]

Answers to those seven put you in a position to read a price sheet properly. Then take the current figures from the pages that date them: the price tracker and the cheapest semaglutide board.